Actavis' Viberzi, Valeant's Xifaxan OK'd in IBS-D in US

The FDA on 27 May approved Actavis' and Patheon Pharmaceuticals' Viberzi (eluxadoline) and Valeant's and its subsidiary Salix's Xifaxan (rifaximin) to treat adults with irritable bowel syndrome with diarrhea (IBS-D).